10-K 1 form10ksb.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: July 31, 2003 [_] TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File No. 2-96510-NY DG LIQUIDATION, INC. (Name of registrant as specified in its charter) New Jersey 11-2269958 (State of other jurisdiction of (IRS Employer Identification No.) Incorporation or organization) c/o Med-Care, Building #3, 3535 Route 66, Neptune, NJ 07753 (Address of principal executive offices) (Zip Code) Issuer's telephone number, including area code: (732) 918-7555 Securities registered pursuant to Section 12(b) of the Act: Name of exchange on Title of each class which registered ------------------- ---------------- None None Securities registered pursuant to Section 12(b) of the Act: Title of each class Common Stock, par value $1.00 per share 1 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the "Act") during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes__ No X Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ X ] Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). [ ] State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. There is no trading market and therefore no market value for the registrant's voting common equity securities. Indicate the number of shares outstanding of each of the registrant's class of common stock, as of the latest practicable date: As of July 14, 2004 there were 9,274,863 shares of common stock outstanding. DOCUMENTS INCORPORATED BY REFERENCE None. 2 PART I ITEM 1. BUSINESS. General DG Liquidation, Inc. (formerly known as "Drug Guild Distributors, Inc.", and sometimes referred to as the "Company" or the "Registrant"), was previously engaged in wholesale distribution of a wide variety of products almost exclusively to drugstores and health and beauty product stores primarily in the State of New Jersey and the Greater New York City metropolitan area. Since the sale of assets to Neuman Health Services, Inc. and Neuman Distributors, Inc. in July 1997, the Company has been operating under a liquidation plan and its financial reporting is now made in accordance with the liquidation basis of accounting. Therefore, all discussions in this annual report relate to the Company in liquidation. Asset Sale On July 3, 1997, the Company sold substantially all of its operating assets, subject to substantially all of the Company's liabilities, to Neuman Health Services, Inc. and Neuman Distributors, Inc. (collectively "Neuman"), wholesale distributors of pharmaceuticals and health and beauty products. A Plan of Complete Liquidation (the "Liquidation Plan") was approved by the holders of a majority of the Company's outstanding shares of common stock on June 27, 1997. The Liquidation Plan provided for: (1) sale of the Company's operating assets, (2) payment of or provision for all of the Company's remaining liabilities and obligations, (3) payment of $100 per share to holders of preferred stock prior to any amount distributed to the common stockholders and (4) the dissolution of the Company. The purchase price was composed of $4,000,000 in cash paid on closing, an unsecured $1,000,000 non-interest bearing promissory note due in August 2001, and an adjustable value promissory note recorded at $10,646,000 payable in quarterly installments over four years and collateralized by a standby letter of credit. Neuman also agreed to assume and to pay, perform or discharge certain specified liabilities of the Company, including leases, trade accounts payable, accrued expenses as reflected on the closing balance sheet, the collective bargaining agreement with the union local representing former employees, expenses incurred in the ordinary course of business, bank debt and long term notes. However, Neuman did not assume severance or termination payments, worker compensation claims, liability for any federal, state or local taxes, environmental claims, undisclosed or contingent liabilities, penalties, Drug Enforcement Administration fines or liabilities with respect to the preferred stock of the Company. The adjustable value note provided for interest at a rate determined quarterly equal to the higher of 1% plus the 180-day London Interbank Offered Rate or the rate specified for U.S. Treasury Notes with maturity equal to the remaining term of the note, but no lower than the Federal rate as disseminated by the Internal Revenue Service from time to time. Payments on the adjustable value promissory were made by Neuman until May 2000, when Neuman defaulted in making the required payments. The Company received $7,084,000 from the standby letter of credit as result of Neuman's default. 3 In connection with the sale, the Company received an option in favor of the Company's stockholders to purchase, under certain conditions, an aggregate of 10% of Neuman shares to be made available in a public offering in the event Neuman filed a registration statement with the Securities and Exchange Commission prior to July 3, 2001, at a price equal to 85% of the per share public offering price. Since no registration statement was been filed by Neuman prior to July 3, 2001, the option lapsed. The asset purchase agreement provided that the purchase price was subject to adjustment based upon a final valuation of the assets and liabilities sold. The terms of sale also provided that Neuman had one year from the date of purchase to return to the Company any accounts receivable balances which had not then been collected and reduce the amount of the adjustable note by such uncollected balances. On or about July 1, 1998, Neuman proposed to reassign to the Company uncollected accounts receivable of four customers which accounted for approximately $1,486,000. The Company rejected Neuman's proposal and claimed that, pursuant to the provisions of the asset purchase agreement, it was entitled to receive the full amount of the pre-acquisition balance due of $1,486,000 out of a pending payment by a major pharmaceutical retail chain to Neuman of approximately $2,500,000. This disagreement between Neuman and the Company was ended by Neuman's bankruptcy in 2000 (see below) and the uncollected accounts receivable of $1,486,000 were not reassigned to the Company. On April 6, 2000, Neuman filed a petition for reorganization under Chapter 11 of the Bankruptcy Code. As a result, the Company wrote off the then $880,000 carrying value of Neuman's unsecured promissory note as uncollectible. Neuman's bankruptcy petition constituted an "event of default" under the terms of the secured adjustable value promissory note. By reason of Neuman's default, and on May 22, 2000, the Company made a drawing on the standby letter of credit which collateralized the note. On May 25, 2000, the Company received $7,084,000, of which $2,794,000 represented the carrying value of the adjustable rate note, $102,000 represented accrued interest thereon through such date and $4,188,000 represented additional proceeds. Within the ninety-day period prior to the filing of the Neuman bankruptcy petition, the Company had received $885,000 of quarterly payments from Neuman in connection with the adjustable value note. Subsequent to the filing of the Neuman bankruptcy petition, the Chapter 11 Trustee filed a complaint against the Company in the Bankruptcy Court seeking to recover the $885,000 as a preference payment. The Company filed an answer including defenses against the Trustee's claims and filed a motion for summary judgment. October 20, 2000, the Company also filed a general unsecured claim against the Neuman bankruptcy estate which reflected $7,657,000 due from Neuman on the adjustable value note at March 31, 2000, including $576,000 of additional accrued interest through such date based on the increased amount of the note, prior to the receipt of the $7,084,000 letter of credit proceeds, leaving a balance of $573,000 due the Company. In addition, the Company filed a claim for $1,000,000 in connection with the unsecured note. 4 On September 24, 2002, a settlement agreement was entered into pursuant to which the Company and the Trustee released each other from all pre-petition or post-petition claims, except that the Company was entitled to receive distribution from the bankruptcy estate with respect to its unsecured claims, referred to above, which were allowed in full. The settlement agreement was approved by the Bankruptcy Court on October 9, 2002. See Note A-2 to the financial statements with respect to the recording of $4,188,000 as additional gain. As of the date of this report, no additional distribution has been made to the Company from the Neuman bankruptcy estate and there is no assurance that any additional distributions will be made in the future. Employees The Company has oral consulting agreements with its President, Harold Blumenkrantz, and a director, Michael Katz, and a written consulting agreement with Jay Reba, its former Vice President-Finance, for the purpose of implementing the Liquidation Plan. The terms of the consulting agreement with Mr. Blumenkrantz provided for his part-time employment on a month-to-month basis for a consulting fee of $5,000 per month, plus reasonable and customary expenses. Mr. Blumenkrantz ceased collecting his consulting fee after July 31, 2001. Michael Katz received a consulting fee of $1,000 per month for assistance in liquidation activities until the end of April 2002. The written consulting agreement with Mr. Reba is dated June 4, 1998, and provided for his consulting services for a minimum of three months, and on a month-to-month basis thereafter, for a consulting fee of $11,400 per month (beginning in January 1999), plus reasonable and customary expenses and a severance payment of $34,200. Mr. Reba's consulting agreement terminated August 31, 1999. He was thereafter engaged by the Company on a month-to-month basis to render limited consulting services for a fee of $2,750 per month from September 1, 1999 until April 30, 2002. His current engagement by the Company provides for payment to him of $125 per hour, plus expense reimbursement, for work he is asked to perform. Competition. Competition is no longer a material factor for the Company, since it is engaged only in implementing its Liquidation Plan and is not actively engaged in business as a going concern. ITEM 2. PROPERTIES. The Company occupies office space, on a month-to-month basis, in the offices of its President, Harold Blumenkrantz, in Neptune, New Jersey and in Boca Raton, Florida, at an annual cost, including telephone service, photocopies and postage, of $1,200. 5 ITEM 3. LEGAL PROCEEDINGS. DG Liquidation, Inc. v. Anchin, Block & Anchin, LLP. --------------------------------------------------- On March 3, 1998, the Company filed a complaint in New York County Supreme Court against its former auditors, Anchin, Block & Anchin, LLP (the "Anchin Firm"), seeking to recover damages for professional malpractice, breach of fiduciary duty and breach of contract exceeding $16,000,000 in connection with inventory defalcations during the period of October 1992 through May 1996. The Anchin Firm had previously acted in the capacities of financial advisors, auditors and accountants for the Company for a continuous period beginning in 1977 and ending on July 2, 1996. On April 30, 1998, the Anchin Firm filed an answer denying the material allegations, and commenced a third-party lawsuit against members of the Company's Executive Committee during the period of January 1990 through May 31, 1996, and the Company's corporate attorneys, alleging that if the Company was successful in its claims against the Anchin Firm, then these third-party defendants should be held liable for the losses to the Company by reason of an alleged failure to reasonably perform their respective fiduciary duties. On October 27, 1998, the court dismissed all of the third-party claims against the Company's corporate attorneys and the Anchin Firm withdrew its claims against the former members of the Executive Committee. The Company's claims against the Anchin Firm were tried before a jury in Supreme Court, New York County in October and November 2002, which resulted in a verdict in favor of the Company. Judgment in favor of the Company and against the Anchin Firm was entered in Supreme Court, New York County on February 4, 2003. The judgment was paid in full on May 16, 2003 in the total sum of $297,000. See Note E-1 to the financial statements. Claim of Daniel Kantor Mr. Kantor is a former director of the Company who owns or controls approximately 134,000 shares of the Company's common stock. In October 1996, the Company received a letter from an attorney for Mr. Kantor alleging mismanagement of the Company and requesting additional information. In June 1997, the attorney, acting on behalf of Mr. Kantor and other stockholders who appear to be related to Mr. Kantor, asked for copies of the Company's financial statements over the past three years, which the Company supplied. As of the date of this report, no other action has taken place with regard to this matter. Michael's Pharmacy and Michael Scicutella v. Drug Guild Distributors, Inc., et al. The plaintiff, a customer of Drug Guild, initiated this lawsuit in February 1997 in the United States District Court for the District of New Jersey, alleging that the Company has conspired with co-defendant wholesalers, McKesson Corp., Cardinal Health Company, W. Daly, Inc. and Remo Drug Corp. to deny credit to the plaintiff that was allegedly due to it, amounting to an alleged "group boycott" in violation of the federal Sherman Anti-trust Act and New Jersey's Anti-trust Act, as well as an alleged breach of an implied covenant of good faith and fair dealing, and tortious interference with the plaintiff's contracts. 6 The plaintiff asked for preliminary and permanent injunctions as well as a money judgment against each defendant for what were described as actual, compensatory, punitive and trebled damages, attorney's fees and costs, and such other relief as the court found appropriate. The court denied the plaintiff's requests for a preliminary injunction. The Company filed an answer denying all of the material allegations of the complaint, setting forth various affirmative defenses, alleging a counterclaim against the plaintiff for approximately $48,000 owed to the Company, and asked for a dismissal of the complaint. The defendants, including the Company, made motions for summary judgment seeking dismissal of all of the plaintiff's claims. The Company also asked for summary judgment on its counterclaim. On August 12, 2002, all of the claims were formally dismissed by the court. The Company has been a party to several other pending legal actions, principally motor vehicle accidents involving vehicles owned or operated by the Company, and other claims, including products liability, for which the Company is covered by insurance. The results of these various lawsuits and claims will not materially affect the financial position of the Company. ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS There were no matters submitted to a vote of the Company's security holders during the fiscal year ended July 31, 2003 through the solicitation of proxies or otherwise. PART II ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS. There is no existing public market for any of the Company's securities. As of July 14, 2004, there were approximately 366 holders of record of the Company's common stock, and all of the Company's preferred stock has been redeemed. The Company has never paid a cash dividend and does not expect to pay cash dividends in the future. As of the date of this report, liquidation payments have been made to preferred stockholders ($2,262,000) and common stockholders ($15,785,000, with a reserve of $39,000 for certain stockholders who could not be located), and additional liquidation payments will be made to the Company's common shareholders in accordance with the provisions of the Liquidation Plan. ITEM 6. SELECTED FINANCIAL DATA This table has been omitted because the Company's financial reporting is now being made on the liquidation basis of accounting. See Item 8 - Financial Statements and Supplementary Data. 7 ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Since July 1, 1997, the Company has been operating under the Liquidation Plan and its financial reporting is being made in accordance with the liquidation basis of accounting. Therefore, the following discussion relates to the financial statements presented on a liquidation basis. Statement of Net Assets in Liquidation Pursuant to the Liquidation Plan, the Company sold substantially all of its operating assets on July 3, 1997, subject to substantially all of the Company's liabilities, for an aggregate price of $4,000,000 in cash paid at the closing, an unsecured, non interest bearing promissory note for $1,000,000 due August 2001 and an adjustable value promissory note recorded for $10,646,000 payable over four years with interest at 1% above the 180-day Libor rate and collateralized by an irrevocable standby letter of credit. The $1,000,000 promissory note was recorded at its then present value of approximately $766,000. The purchase price was subject to additional adjustment based on the final valuation of the assets and liabilities sold. In addition, the buyer had the right to return any receivables not paid after one year from the sale. As of July 31, 2002, the Company had collected an aggregate total of $12,063,000 of payments made on the adjustable rate promissory note, of which $10,646,000 was applied to notes receivable and the remaining $1,417,000 to interest. In the year ended July 31, 2000, the Company wrote off the carrying value of $880,000 of the unsecured promissory note. The Company set aside as accrued and estimated liquidation expenses an amount believed to be adequate for payment of all expenses and other known liabilities as well as likely and quantifiable contingent obligations, including potential tax obligations. In the event this accrued and estimated liquidation expense is not adequate for payment of the Company's expenses and liabilities, each stockholder could be held liable for pro rata payments to creditors in an amount not to exceed the stockholder's prior distributions from the Company. The Company has therefore adopted a conservative policy of retaining sufficient assets to insure against any unforeseen and non-quantifiable contingencies. Statement of Changes in Net Assets in Liquidation As of July 31, 2003, the Company had net assets in liquidation of $2,442,000. This represented an increase in estimated liquidation value of assets over liabilities of $957,000 from the net assets at July 31, 2002. This increase was mainly attributed to the additional gain on sale of assets of $2,513,000, net of $1,675,000 income taxes. This was reduced by a liquidating distribution to common shareholders of $1,856,000. The increase in net assets also included interest income of $37,000, collection of accounts receivable previously written off of $342,000 and by decreased other expenses of $16,000. In addition, the net proceeds from the judgment against Anchin was $6,000 net of expenses of $291,000. The provision for income taxes related to the increase in net assets was $1,777,000. 8 ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. Not applicable. ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA. See the index constituting a part of Item 15. ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE. Not applicable. ITEM 9A. CONTROLS AND PROCEDURES Evaluation of Disclosure Controls and Procedures. As required by Rule 13a-15 under the Act, within the 90 days prior to the filing date of this report, the Company carried out an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures. This evaluation was carried out under the supervision of the Company's management, the President and Chief Executive Officer and Secretary, Treasurer, Principal Financial and Accounting Officer. Based upon that evaluation, the Company's President, Chief Executive Officer and Principal Financial and Accounting Officer have concluded that the Company's disclosure controls and procedures are currently effective in timely alerting them to material information relating to the Company required to be included in the Company's periodic SEC filings. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in Company reports filed or submitted under the Act is recorded, processed, summarized and reported, within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in Company reports filed under the Act is accumulated and communicated to management, which consists only of the Company's President and Chief Executive Officer and Secretary, Treasurer, Principal Financial and Accounting Officer, to allow timely decisions regarding required disclosures. Changes in Internal Controls. There have been no changes in internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. 9 PART III ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT. In connection with adoption of the Liquidation Plan in June 1997, the Company's shareholders approved elimination of staggered terms for members of the Board of Directors and reduced the number of members from 34 to 7. The following individuals served as directors and executive officers of the Company during the fiscal year ended July 31, 2003:

The Company's officers hold office until the next annual meeting of the Company's Board of Directors and until their respective successors are elected. Harold Blumenkrantz has been a member of the Executive Committee of the Company's Board of Directors for more than the past five years and was appointed President in June 1997. He has been a principal of West End Family Pharmacy, Inc., Long Branch, New Jersey, since 1962. Alfred Hertel has been an officer and director of the Company and an officer and a principal shareholder of Oakland Drug Inc., located in Oakland, New Jersey, for more than the past five years. Michael Katz was principal of Katz Drug, Brooklyn, New York and is now retired. Mr. Katz has been a director of the Company since 1976 and a vice president of the Company since June 1997. Gerald Koblin has been a principal of Koblin Pharmaceuticals, Inc., Nyack, New York for more than the past five years. Mr. Koblin has been a director of the Company since 1995, the Secretary and Treasurer since July 1997, and the Chief Accounting and Financial Officer of the Company since August 1997. Paul Emmanuel had been the owner of Town and Country Pharmacy, Inc., Ridgewood, New Jersey, for more than the past five years before he sold the store in 2000. Mr. Emmanuel has been a director of the Company since 1985. 10 Ernest Wyre (deceased December 14, 2003) was a principal of Lenox Terrace Drugstore, Inc. and Fairview Chemists, Brooklyn, New York for more than five years prior to 1987, and since that time has been a private investor. Mr. Wyre has been a director of the Company since 1976. ITEM 11. EXECUTIVE COMPENSATION. Summary Compensation Table The following table sets forth, for the fiscal years ended July 31, 2003, 2002 and 2001, the cash compensation paid by the Company, as well as certain other compensation paid with respect to those years, to the chief executive officer and each of the four other most highly compensated executive officers of the Company in all capacities in which they served.

None of the directors or members of the Executive Committee received any direct remuneration from the Company or reimbursement for expenses, except that Michael Katz received a consulting fee of $1,000 per month for assistance in liquidation activities until the end of April 2002 and the Company reimburses minor amounts of expenses on an infrequent basis. None of the directors or members of the Executive Committee received any direct remuneration from the Company or reimbursement for expenses, except that Michael Katz received a consulting fee of $1,000 per month for assistance in liquidation activities until the end of April 2002 and the Company reimburses minor amounts of expenses on an infrequent basis. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 11 The following table sets forth certain information regarding shares of common stock beneficially owned as of July 14, 2004, by (i) each person, known to the Company, who beneficially owns more than 5% of the common stock, (ii) each of the Company's directors and (iii) all officers and directors as a group:

(1) All of these shares are owned of record. Common Stock 12 The Company is authorized to issue up to 25,000,000 shares of common stock, $1.00 par value each, of which 9,274,863 shares are currently issued and outstanding. The holders of common stock are entitled to one vote for each share held of record on all matters to be voted on by shareholders, and are entitled to receive dividends when and if declared by the Board of Directors out of funds legally available therefore. The common stock has no conversion, preemptive or other subscription rights, and there are no redemption provisions applicable to the common stock (except for the Company's right of first refusal, discussed below). There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares of common stock can elect all of the directors. Holders of the common stock who are customers of the Company are required to pledge their shares to the Company as security for their purchase of products. All holders who intend to sell their shares are required to first offer them to the Company (the "right of first refusal") at a purchase price equal to the lesser of (a) the book value of the shares or (b) the greater of cost or par value. If the Company elects to exercise its right of first refusal, it must pay for the shares in three equal annual installments, without interest, commencing 60 days after the offer is made. In the event of liquidation, dissolution or winding up of the Company, such as that being implemented the Liquidation Plan, the owners of common stock are entitled to share all assets remaining available for distribution after the payment of liabilities and after provision has been made for each class stock, if any, having a preference over the common stock as such. Preferred Stock The Company is authorized to issue up to 250,000 shares of preferred stock, $100 par value each. Preferred stockholders are entitled to an 8% cumulative dividend based on par value, payable in preferred stock. Upon liquidation of the Company, holders of the preferred stock are entitled to a payment of $100 per share before any amounts are paid to holders of common stock. The preferred stock is not entitled to vote and does not have any preemptive or conversion rights. Holders of preferred stock have the right to require the Company to repurchase their shares at par value ($100.00) commencing five years after full payment for the stock has been made. The Company may call preferred stock at any time. The call price is 105% of par value if shares are called within the first year of issue, 110% of par value within the second year, 115% within the third year, 120% within the fourth year and 125% after four years. A holder of shares of preferred stock desiring to sell his shares to a third party must first offer them to the Company at the repurchase price. If the Company elects to accept such offer, it is obligated to pay for such shares in three equal annual installments, without interest, the first such installment to be made 60 days after such offer. As of July 31, 2003, there were no shares issued and outstanding. 13 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS. The Company has oral consulting agreements with its President, Harold Blumenkrantz, and a director, Michael Katz, and a written consulting agreement with Jay Reba, its former Vice President-Finance, for the purpose of implementing the Liquidation Plan. The terms of the consulting agreement with Mr. Blumenkrantz provided for his part-time employment on a month-to-month basis for a consulting fee of $5,000 per month, plus reasonable and customary expenses. Mr. Blumenkrantz ceased collecting his consulting fee after July 31, 2001. Michael Katz received a consulting fee of $1,000 per month for assistance in liquidation activities until the end of April 2002. The written consulting agreement with Mr. Reba is dated June 4, 1998, and provided for his consulting services for a minimum of three months, and on a month-to-month basis thereafter, for a consulting fee of $11,400 per month (beginning in January 1999), plus reasonable and customary expenses and a severance payment of $34,200. Mr. Reba's consulting agreement terminated August 31, 1999. He was thereafter engaged by the Company on a month-to-month basis to render limited consulting services for a fee of $2,750 per month from September 1, 1999 until April 30, 2002. His current engagement by the Company provides for payment to him of $125 per hour, plus expense reimbursement, for work he is asked to perform. The Company occupies office space, on a month-to-month basis, in the offices of its President, Harold Blumenkrantz, in Neptune, New Jersey, and Boca Raton, Florida, at an annual cost, including telephone service, photocopies and postage, of $1,200. No other officer or director received any direct remuneration from the Company or reimbursement for expenses, except that the Company reimburses minor amounts of expenses on an infrequent basis. ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES AUDIT FEES The aggregate fees billed by Eisner LLP for the annual audit and review of the interim financial statements were approximately $17,000 and $17,000 for the fiscal years ended July 31, 2003 and 2002, respectively. AUDIT RELATED FEES Eisner LLP did not render any professional services to DG Liquidation, Inc. involving "Audit Related Fees" other than as set forth in the preceding paragraph. TAX FEES Eisner LLP did not render any professional services to DG Liquidation, Inc. during the fiscal years ended July 31, 2003 and 2002 for tax compliance, tax advice and tax planning services. ALL OTHER FEES The aggregate fees billed by Eisner LLP for all other services rendered to DG Liquidation, Inc. during the fiscal years ended July 31, 2003 and 2002, other than audit services, were approximately $16,000 and $3,000, respectively. These "other fees" were for services related to the Anchin lawsuit and tax return preparation. 14 ITEM 15. EXHIBITS, FINANCIAL STATEMENTS, FINANCIAL STATEMENT Schedules and Reports on Form 8-K (a)(1) Financial Statements. The following are filed with this report: (i) Independent Auditors' Report. (ii) Statement of Net Assets (liquidation basis) at July 31, 2003 and 2002. (iii) Statement of Changes in Net Assets (liquidation basis) for the years ended July 31, 2003, 2002 and 2001. (iv) Notes to the Financial Statements. (a)(2) Financial Statement Schedules: None (a)(3) Exhibits. The following exhibits are filed as part of this report: Exhibit Number Exhibit -------------- ------- 31 Rule 13(a)-15(e)/15(d)-15(e) Certifications. 32 Section 1350 Certification (b) Reports on Form 8-K No reports on Form 8-K were filed during the last quarter of fiscal 2003. 15 SIGNATURES Pursuant to the requirements of the Securities Act of 1934, the Registrant has duly caused this amended Section 13 or 15(d) report to be executed on its behalf by the undersigned, thereunto duly authorized, in the Town of Neptune, State of New Jersey, on July 14, 2004 DG LIQUIDATION, INC. By: /s/ Harold Blumenkrantz ----------------------- Harold Blumenkrantz, President President and Chief Executive Officer Pursuant to the requirements of the Securities Exchange Act of 1934, this amended report has been signed by the following person on behalf of the Registrant and in the capacity and on the date indicated.

16 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Board of Directors and Stockholders DG Liquidation, Inc. We have audited the accompanying statements of net assets (liquidation basis) of DG Liquidation, Inc. as of July 31, 2003 and 2002 and the related statements of changes in net assets (liquidation basis) for each of the three years in the period ended July 31, 2003. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. As described in Note A to the financial statements, the stockholders of the Company approved a plan of liquidation on June 27, 1997 and on July 3, 1997, the Company sold substantially all its net assets and commenced liquidation proceedings. As a result, the Company has changed its basis of accounting for periods subsequent to June 30, 1997 from the going concern basis to a liquidation basis. In our opinion, the financial statements referred to above present fairly, in all material respects, the net assets in liquidation of DG Liquidation, Inc. as of July 31, 2003 and 2002 and the changes in its net assets in liquidation for each of the three years in the period ended July 31, 2003, in conformity with accounting principles generally accepted in the United States of America applied on the liquidation basis as described in the preceding paragraph. Eisner LLP New York, New York October 24, 2003 F-1 DG LIQUIDATION, INC. (formerly known as Drug Guild Distributors, Inc.) STATEMENTS OF NET ASSETS (liquidation basis) (in thousands, except share and per share amounts)

See notes to financial statements F-2 DG LIQUIDATION, INC. (formerly known as Drug Guild Distributors, Inc.) STATEMENTS OF CHANGES IN NET ASSETS (liquidation basis) (in thousands, except share and per share amounts)

See notes to financial statements F-3 DG LIQUIDATION, INC. (formerly known as Drug Guild Distributors, Inc.) NOTES TO FINANCIAL STATEMENTS JULY 31, 2003 AND 2002 NOTE A - PLAN OF LIQUIDATION, SALE OF ASSETS AND BASIS OF PRESENTATION [1] PLAN OF LIQUIDATION: DG Liquidation, Inc. (the "Company"), formerly known as Drug Guild Distributors, Inc., was a wholesale distributor of a wide variety of products to drug stores and health and beauty aid stores located primarily in the State of New Jersey, the greater New York City metropolitan area and Connecticut. A Plan of Complete Liquidation (the "Plan") was approved by the holders of a majority of the Company's outstanding shares of common stock on June 27, 1997. The Plan provided for: (1) the sale of the Company's operating assets, (2) the payment of or provision for all of the Company's remaining liabilities and obligations, (3) payment of $100 per share to the holders of preferred stock prior to any amounts distributed to the common stockholders and (4) the dissolution of the Company. [2] SALE OF ASSETS: On July 3, 1997, the Company sold substantially all of its operating assets, subject to substantially all of the Company's liabilities, to Neuman Health Services, Inc. and Neuman Distributors, Inc. (collectively "Neuman"), wholesale distributors of pharmaceuticals and health and beauty products, for $4,000,000 in cash paid on closing, an unsecured $1,000,000 noninterest bearing promissory note due in August 2001 and the remainder in an adjustable value promissory note, recorded at $10,646,000, payable in quarterly installments over four years and collateralized by a standby letter of credit. The $1,000,000 promissory note was recorded at its present value using an imputed interest rate of 6.69%. The adjustable value note provided for interest at a rate determined quarterly equal to the higher of 1% plus the 180-day London Interbank Offered Rate or the rate specified for U.S. Treasury Notes with maturity equal to the remaining term of the note, but no lower than the Federal rate as disseminated by the Internal Revenue Service from time to time. During the year ended July 31, 1998, pursuant to the terms of the note, interest was paid quarterly based on the principal payments received by the Company. Subsequent thereto, interest was payable quarterly based on the unpaid principal balance of the note. The asset purchase agreement provided that the purchase price would be subject to adjustment based upon a final valuation of the assets and liabilities sold. In addition, the terms of sale provided that Neuman had one year from the date of purchase to return to the Company any accounts receivable balances which had not then been collected and reduce the amount of the adjustable note by such uncollected balances (see Note E[2]). The gain recognized on the sale was $3,683,000. On April 6, 2000, Neuman filed a petition for reorganization under Chapter 11 of the Bankruptcy Code. As a result thereof, during the year ended July 31, 2000, the Company wrote off their $880,000 carrying value of the unsecured promissory note due from Neuman. In addition, on May 22, 2000 the Company made a drawing on the standby letter of credit and on May 25, 2000 received $7,084,000 of which $2,794,000 represented the carrying value of the adjustable value note, $102,000 represented accrued interest thereon through such date and $4,188,000 represented additional proceeds. F-4 DG LIQUIDATION, INC. (formerly known as Drug Guild Distributors, Inc.) NOTES TO FINANCIAL STATEMENTS JULY 31, 2003 AND 2002 NOTE A - PLAN OF LIQUIDATION, SALE OF ASSETS AND BASIS OF PRESENTATION (CONTINUED) [2] SALE OF ASSETS: (CONTINUED) Within the ninety-day period prior to the filing of the petition, the Company received $885,000 from Neuman in connection with the adjustable value note. Subsequent to the filing, the Chapter 11 Trustee filed a complaint against the Company in the Bankruptcy Court to recover such alleged preference payment. The Company maintained that it had defenses against the Trustee's claims and filed a motion for summary judgment. In addition, on October 20, 2000, the Company filed a general unsecured claim against the bankruptcy estate which reflected that $7,657,000 was due from Neuman on the adjustable value note at March 31, 2000, including $576,000 of additional accrued interest through such date based on the increased amount of the note, prior to the receipt of the $7,084,000 letter of credit proceeds, leaving a balance of $573,000 due the Company. In addition, the Company filed a claim for $1,000,000 in connection with the unsecured note. On September 24, 2002, a settlement agreement, which was approved by the Bankruptcy Court on October 9, 2002, was entered into pursuant to which the Company and the Trustee released each other from all pre-petition or post-petition claims, except that the Company is entitled to receive distribution from the bankruptcy estate as to its unsecured claims referred to above which were allowed in full. Accordingly during fiscal 2003, the Company recorded an additional gain on sale of its assets of $4,188,000. [3] BASIS OF PRESENTATION: Subsequent to June 30, 1997, the Company adopted the liquidation basis of accounting. Accordingly, the net assets of the Company at July 31, 2003 and 2002 are stated at liquidation value whereby assets are stated at their estimated net realizable values and liabilities, which include estimated liquidation expenses to be incurred through the date of final dissolution of the Company, are stated at their anticipated settlement amounts. The valuation of assets and liabilities necessarily requires estimates and assumptions. Net assets and future liquidating distributions will be subject to uncertainties including the ultimate amount of liquidation expense and the amount, if any, ultimately collected on unsecured claims against the bankruptcy estate. F-5 DG LIQUIDATION, INC. (formerly known as Drug Guild Distributors, Inc.) NOTES TO FINANCIAL STATEMENTS JULY 31, 2003 AND 2002 NOTE B - ESTIMATED LIQUIDATION EXPENSES Estimated liquidation expenses, consisting of legal and other professional fees, consulting fees and insurance expense, to be incurred through the date of final dissolution of the Company have been accrued in the accompanying financial statements. Analysis of transactions reflected in the liability for estimated liquidation expenses during fiscal 2001, 2002 and 2003 follows:

F-6 DG LIQUIDATION, INC. (formerly known as Drug Guild Distributors, Inc.) NOTES TO FINANCIAL STATEMENTS JULY 31, 2003 AND 2002 NOTE C - INCOME TAXES The Company accounts for income taxes utilizing the asset and liability approach requiring the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and tax purposes. The net deferred tax asset at July 31, 2003 and 2002 relates to the following:

For the year ended July 31, 2002, the gain from life insurance policy proceeds which amounted to $1,511,000, although exempt from regular corporate income tax, resulted in an alternate minimum tax of $215,000 which is included in the provision for income tax in the accompanying statements of changes in net assets. Although the alternative minimum tax ("AMT") is available as a credit against the regular tax liability in future years and is therefore included as deferred tax assets, a valuation allowance has been provided against such amount as the amount of credit which will ultimately be realized is uncertain. During the year ended July 31, 2003, $50,000 of the AMT credit was used to offset the regular tax liability leaving a remaining AMT credit carryover of $165,000 at July 31, 2003. NOTE D - OFFICER'S LIFE INSURANCE The Company was the owner and beneficiary of insurance policies of $1,600,000, on the life of its former president. In December 2001, subsequent to the death of the Company's former president, the Company received approximately $1,599,000, net of outstanding loans of $157,000 from the insurance company in settlement of the policies, resulting in a gain of $1,511,000 in fiscal 2002. NOTE E - COMMITMENT AND CONTINGENCIES [1] On March 3, 1998, the Company filed a complaint in Supreme Court of the State of New York, in New York County, against its former auditors, Anchin, Block & Anchin, LLP (the "Anchin Firm") seeking to recover damages for professional malpractice, breach of fiduciary duty and breach of contract exceeding $16,000,000 in connection with an inventory defalcation. The Anchin Firm had previously acted in the capacities of financial advisors, auditors and accountants for the Company for a continuous period beginning in 1977 and ending on July 2, 1996. The damages sought from the Anchin Firm relate to the loss of inventory by reason of the defalcations taking place during the period from October 1992 through May 1996, a reduction in the consideration received in the asset sale transaction with Neuman and restitution of approximately $900,000 of fees paid to the Anchin Firm and various other fees and expenses. F-7 DG LIQUIDATION, INC. (formerly known as Drug Guild Distributors, Inc.) NOTES TO FINANCIAL STATEMENTS JULY 31, 2003 AND 2002 NOTE E - COMMITMENT AND CONTINGENCIES (CONTINUED) [1] (continued) On April 30, 1998, the Anchin Firm filed an answer denying the material allegations, and commenced a third-party lawsuit against members of the Company's Executive Committee during the period of January 1990 through May 31, 1996, and the Company's corporate attorneys, alleging that if the Company is successful in its claims against the Anchin Firm, then these third-party defendants, by reason of their alleged failure to reasonably perform their respective fiduciary duties, should be held liable for the losses to the Company for which the Anchin Firm is sought to be held responsible. On October 27, 1998, the court dismissed the third-party claims against the Company's corporate attorneys and the Anchin Firm withdrew its claims against the former members of the Executive Committee, thereby discontinuing the third-party lawsuit. The Company's claims against the Anchin Firm were tried before a jury in Supreme Court, New York County, in October and November 2002, which resulted in a verdict in favor of the Company. Judgment in favor of the Company and against the Anchin Firm was entered in Supreme Court, New York County, on February 4, 2003 in the aggregate sum of approximately $290,000. The judgment was paid in full on May 16, 2003 in the total sum of $297,000, including interest of $7,000, which amount net of legal expense of $291,000, is included as gain on settlement of litigation in the statement of changes in net assets for the year ended July 31, 2003. [2] On or about July 1, 1998, the buyer of the Company's assets (Neuman) proposed to reassign to the Company uncollected accounts receivable of four customers which accounted for approximately $1,486,000 of accounts receivable purchased from the Company in July 1997 (see Note A[2]). The Company had assigned those accounts receivable to Neuman together with related security agreements. After the closing of the asset purchase Neuman made additional sales to those four customers and extended additional credit to them. Neuman also incurred legal fees and interest in seeking to collect both the pre-closing and post-closing accounts receivable with the result that Neuman asserted that it has made a post-closing extension of credit to the four customers totaling approximately $2,336,000. Neuman had told the Company that it should accept reassignment of the accounts receivable of the four customers in an aggregate total of $1,486,000 without reassignment of the security agreements, with a corresponding reduction in the adjustable value note receivable. The Company had taken the position that the security agreements must follow the accounts receivable which they secure and that it is therefore not obligated to accept reassignment of the accounts receivable, and therefore a reduction in the face amount of the note, unless it also receives the security agreements applicable to those accounts receivable. The Company had told Neuman that pursuant to the asset purchase agreement, the oldest accounts receivable must be paid in full before the newer accounts receivable are paid and that it was therefore entitled, under the security agreements which must be reassigned together with the accounts receivable, to receive the full amount of the pre-acquisition balance due of $1,486,000 out of a pending payment by a major pharmaceutical retail chain to Neuman of approximately $2,500,000. As described in Note A[2], a settlement agreement was approved by the Bankruptcy Court on October 9, 2002, pursuant to which the Trustee in Neuman's bankruptcy and the Company released each other from all pre-petition or post-petition claims and, accordingly, none of the accounts receivable were reassigned to the Company. F-8 DG LIQUIDATION, INC. (formerly known as Drug Guild Distributors, Inc.) NOTES TO FINANCIAL STATEMENTS JULY 31, 2003 AND 2002 NOTE E - COMMITMENT AND CONTINGENCIES (CONTINUED) [3] A customer of the Company initiated a lawsuit in February 1997 in the United States District Court for the District of New Jersey, alleging that the Company had conspired with co-defendant wholesalers to deny credit to the plaintiff that is allegedly due to it, amounting to an alleged "group boycott" in violation of the federal Sherman Anti-trust Act and New Jersey's Anti-trust Act, as well as a breach of an implied covenant of good faith and fair dealing and tortuous interference with the plaintiff's contracts. The plaintiff asked for preliminary and permanent injunctions as well as a money judgment against each defendant for what were described as actual, compensatory, punitive and trebled damages, attorney's fees and costs and such other relief as the court may deem appropriate. The court did not enter any preliminary injunction against any defendant. The Company filed an answer denying all of the material allegations of the complaint, setting forth various affirmative defenses, alleging a counterclaim against the plaintiff for the money it owes the Company, approximately $48,000, and asking for a dismissal of the complaint. The defendants, including the Company, had made motions for summary judgment seeking dismissal of all of the plaintiff's claims, which were pending before the court. The Company had also asked for summary judgment on its counterclaim. On August 12, 2002, these claims were dismissed by the court. [4] The Company entered into consulting agreements with its President, a Director and its former Vice President - Finance for the purpose of implementing the plan of liquidation. The agreement with the Company's President provides for his part-time employment on a month-to-month basis for a fee of $5,000 per month plus expenses. The consulting fee for the Director was $1,000 per month and ended in April 2002. The agreement with the former Vice President - Finance commenced on June 4, 1998 and provided for a monthly consulting fee of $11,400 (beginning in January 1999) plus expenses, and a severance payment of $34,000. This agreement terminated in August 1999 and he was engaged thereafter on a month-to-month basis for a fee of $2,750 through April 2002. [5] In connection with the sale of the Company's assets on July 3, 1997, the purchaser assumed the Company's obligation under existing leases and the landlord released the Company from liability for future lease payments. The Company, subsequent to the sale, occupies office space on a month-to-month basis in the offices of its President, at an annual cost including telephone service, photocopies and postage of $1,200. [6] The Company has been a party to several other pending legal actions, principally motor vehicle accidents involving vehicles owned or operated by the Company, and other claims including one for product liability for which the Company is covered by its insurance. The Company believes the results of these various lawsuits and claims will not materially affect the financial position of the Company. F-9

DRUG GUILD DISTRIBUTORS INC 10-K